Format

Send to

Choose Destination
Colloids Surf B Biointerfaces. 2015 Oct 1;134:47-58. doi: 10.1016/j.colsurfb.2015.06.027. Epub 2015 Jun 19.

Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin.

Author information

1
Drug Delivery Research Group, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh 160014, India; Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University, Sagar 470003, MP, India.
2
Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University, Sagar 470003, MP, India; Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA. Electronic address: prashant_pharmacy04@rediffmail.com.
3
Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University, Sagar 470003, MP, India.
4
Drug Delivery Research Group, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh 160014, India.
5
Department of Periodontics, College of Dental Medicine Georgia Regents University, 1120 15th Street, Augusta, GA 30912, USA; Biosafety Support Unit, Regional Centre for Biotechnology-DBT, C.G.O. Complex, Lodhi Road, New Delhi 110003, India.
6
Drug Delivery Research Group, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh 160014, India. Electronic address: drkatare@yahoo.com.

Abstract

The present investigation reports the preparation, optimization, and characterization of surface engineered solid lipid nanoparticles (SLNs) encapsulated with doxorubicin (DOX). Salient features such as biocompatibility, controlled release, target competency, potential of penetration, improved physical stability, low cost and ease of scaling-up make SLNs viable alternative to liposomes for effective drug delivery. Galactosylation of SLNs instructs some gratifying characteristic, which leads to the evolution of promising delivery vehicles. The impendence of lectin receptors on different cell surfaces makes the galactosylated carriers admirable for targeted delivery of drugs to ameliorate their therapeutic index. Active participation of some lectin receptors in immune responses to antigen overlaid the application of galactosylated carriers in delivery of antigen and immunotherapy for treatment of maladies like cancer. These advantages revealed the promising potential of galactosylated carriers in each perspective of drug delivery. The developed DOX loaded galactosylated SLNs formulation was found to have particle size 239 ± 2.40 nm, PDI 0.307 ± 0.004, entrapment efficiency 72.3 ± 0.9%. Higher cellular uptake, cytotoxicity, and nuclear localization of galactosylated SLNs against A549 cells revealed higher efficiency of the formulation. In a nutshell, the galactosylation strategy with SLNs could be a promising approach in improving the delivery of DOX for cancer therapy.

KEYWORDS:

Cytotoxicity; Doxorubicin; Galactose; Lectin; Solid lipid nanoparticles; Targeting

PMID:
26142628
DOI:
10.1016/j.colsurfb.2015.06.027
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center